Rocket One Inc. Common Stock (NASDAQ:RKTO) Trading Up 22.1% – What’s Next?

Rocket One Inc. Common Stock (NASDAQ:RKTO)’s share price was up 22.1% on Wednesday . The stock traded as high as $0.9278 and last traded at $0.90. Approximately 2,248,917 shares were traded during mid-day trading, an increase of 704% from the average session volume of 279,780 shares. The stock had previously closed at $0.7371.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RKTO. Weiss Ratings cut Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. Wall Street Zen lowered Rocket One Inc. Common Stock from a “sell” rating to a “strong sell” rating in a research report on Sunday, August 16th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Rocket One Inc. Common Stock currently has an average rating of “Hold” and a consensus price target of $5.00.

Rocket One Inc. Common Stock Trading Up 22.1%

The stock has a market cap of $20.09 million, a price-to-earnings ratio of -1.10 and a beta of 0.94. The stock’s 50 day moving average is $0.77 and its two-hundred day moving average is $0.87.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.19) EPS for the quarter.

Hedge Funds Weigh In On Rocket One Inc. Common Stock

An institutional investor recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC raised its stake in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 39,000 shares of the company’s stock after acquiring an additional 19,500 shares during the period. Lido Advisors LLC owned approximately 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent SEC filing. 7.08% of the stock is currently owned by institutional investors and hedge funds.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.